Retatrutide has emerged as a new treatment in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately contributes to significant weight loss. While further inv